Nadeu, Ferran https://orcid.org/0000-0003-2910-9440
Royo, Romina https://orcid.org/0000-0003-3493-0874
Massoni-Badosa, Ramon
Playa-Albinyana, Heribert https://orcid.org/0000-0002-3447-3848
Garcia-Torre, Beatriz
Duran-Ferrer, Martí https://orcid.org/0000-0003-1666-5819
Dawson, Kevin J.
Kulis, Marta
Diaz-Navarro, Ander
Villamor, Neus
Melero, Juan L. https://orcid.org/0000-0003-1387-6231
Chapaprieta, Vicente https://orcid.org/0000-0002-4910-5394
Dueso-Barroso, Ana https://orcid.org/0000-0003-2000-9718
Delgado, Julio
Moia, Riccardo https://orcid.org/0000-0001-7393-1138
Ruiz-Gil, Sara
Marchese, Domenica
Giró, Ariadna
Verdaguer-Dot, Núria
Romo, Mónica
Clot, Guillem https://orcid.org/0000-0003-2588-7413
Rozman, Maria
Frigola, Gerard https://orcid.org/0000-0001-6794-6456
Rivas-Delgado, Alfredo https://orcid.org/0000-0003-0385-3415
Baumann, Tycho
Alcoceba, Miguel https://orcid.org/0000-0002-3819-4846
González, Marcos
Climent, Fina
Abrisqueta, Pau
Castellví, Josep https://orcid.org/0000-0001-5745-9996
Bosch, Francesc
Aymerich, Marta
Enjuanes, Anna
Ruiz-Gaspà, Sílvia
López-Guillermo, Armando
Jares, Pedro
Beà, Sílvia https://orcid.org/0000-0001-7192-2385
Capella-Gutierrez, Salvador https://orcid.org/0000-0002-0309-604X
Gelpí, Josep Ll.
López-Bigas, Núria https://orcid.org/0000-0003-4925-8988
Torrents, David
Campbell, Peter J. https://orcid.org/0000-0002-3921-0510
Gut, Ivo https://orcid.org/0000-0001-7219-632X
Rossi, Davide
Gaidano, Gianluca https://orcid.org/0000-0002-4681-0151
Puente, Xose S. https://orcid.org/0000-0001-9525-1483
Garcia-Roves, Pablo M. https://orcid.org/0000-0002-8371-2067
Colomer, Dolors https://orcid.org/0000-0001-7486-8484
Heyn, Holger https://orcid.org/0000-0002-3276-1889
Maura, Francesco https://orcid.org/0000-0002-5017-1620
Martín-Subero, José I. https://orcid.org/0000-0001-8809-5195
Campo, Elías https://orcid.org/0000-0001-9850-9793
Article History
Received: 10 November 2021
Accepted: 1 July 2022
First Online: 11 August 2022
Competing interests
: F.N. has received honoraria from Janssen and AbbVie for speaking at educational activities. J.L.M. is an employee of Omniscope. X.S.P. is cofounder of and holds an equity stake in DREAMgenics. H.H. is cofounder of Omniscope and consultant to MiRXES. E.C. has been a consultant for Takeda, NanoString, AbbVie and Illumina; has received honoraria from Janssen, EUSPharma and Roche for speaking at educational activities; and is an inventor on a Lymphoma and Leukemia Molecular Profiling Project patent ‘Method for subtyping lymphoma subtypes by means of expression profiling’ (PCT/US2014/64161) not related to this project. The remaining authors declare no competing interests.